View detailed financial information, real-time news, videos, quotes and analysis on Passage Bio, Inc. (NASDAQ:PASG). The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. Data Sources. 14.10 15.69. Market Cap. View analysts' price targets for Passage Bio. Revenue) or per share (e.g.
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. Touch device users, explore by touch or with swipe gestures.When autocomplete results are available use up and down arrows to review and enter to select.
Add To Watchlist. Find out the total of insider shares held, purchased and sold.
To explore Passage Bio’s full profile, request a free trial. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options.
* Average Estimates in Million (e.g. Last Updated.
Passage Bio, Inc. operates as a genetic medicines company. 4 brokerages have issued 1 year target prices for Passage Bio's stock.
View real-time stock prices and stock quotes for a full financial overview. PASG | Complete Passage Bio Inc. stock news by MarketWatch. Passage Bio market cap is $1.3 b.. View Passage Bio stock / share price, financial statements, key ratios and more at Craft. The SCOOP ratings should not be taken as investment advice. This suggests a possible upside of 68.7% from the stock's current price. Dividend).
The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow.
Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. View the real-time PASG price chart on Robinhood and decide if you want to buy or sell commission-free. ]Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q2 2020 Results - Earnings Call TranscriptChardan Capital analyst Gbola Amusa reiterated a Buy rating on Passage Bio (PASG) today and set a price target of $32.50.[...] *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Registration on or use of this site constitutes acceptance of our Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
View Passage Bio Inc PASG investment & stock information. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options.
US$678.7m.
Philadelphia, PA 19103 Summary. Touch device users, explore by touch or with swipe gestures.